Signal transduction of RANK and Toll-like receptor in alveolar bone destruction
Signal transduction of RANK and Toll-like receptor in alveolar bone destruction
批准号:
15390565
负责人:
UDAGAWA Nobuyuki
金额:
$9.47万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2003
资助国家:
日本
项目状态:
已结题
起止时间:
2003 至 2004
中文摘要
在细菌引起的炎症性疾病中,脂多糖是一种有效的骨吸收刺激剂。细菌脂蛋白/脂肽也是病原体特异性的分子模式。toll样受体4 (TLR4)被认为是LPS的信号受体。TLR6和TLR2复合物可识别二酰基脂肽。TLR的信号级联与IL-1受体的信号级联相似,因为TLR和IL-1受体都使用MyD88作为共同的信号分子。Toll-IL-1受体结构域适配器诱导的干扰素-γ (TRIF)介导的信号也被证明参与了lps诱导的myd88独立通路。使用MyD88缺失(MyD88^<-/->)小鼠和TRIF缺失(TRIF^<-/->)小鼠,我们研究了MyD88和TRIF在破骨细胞分化和功能中的作用。LPS、二酰基脂肽(DL)和IL-1可刺激TRIF^<-/->小鼠的成骨细胞和造血细胞的共培养,而MyD88^<-/->小鼠则无此作用。MyD88^<-/-> m . More ice和TRIF^<-/->小鼠骨髓造血细胞在RANKL + m - csf作用下相似地分化为破骨细胞。LPS、DL和IL-1可刺激TRIF^<-/->成骨细胞中RANKL mRNA的表达,而对MyD88^<-/->成骨细胞无影响,提示成骨细胞中只有MyD88介导的信号对RANKL的表达起重要作用。这一发现特别有趣,因为myd88依赖途径和trif依赖途径都是巨噬细胞中lps诱导的细胞因子产生所必需的。事实上,LPS不能刺激TRIF^<-/->骨髓巨噬细胞产生IL-6。而脂多糖可以刺激TRIF^<-/->成骨细胞产生IL-6。LPS和IL-1可提高TRIF^<-/->破骨细胞的存活率,但对MyD88^<-/->破骨细胞无作用。DL不支持破骨细胞存活,因为破骨细胞中缺乏TLR6。trf相关适配分子(TRAM)在trf介导的信号通路中起重要作用。有趣的是,巨噬细胞同时表达TRIF和TRAM mRNA,而成骨细胞和破骨细胞仅表达TRIF mRNA。成骨细胞中脂多糖诱导的RANKL和IL-6表达以及破骨细胞存活不需要trif介导的信号,这可能与成骨细胞和破骨细胞中缺乏TRAM表达有关。骨组织形态学测量显示MyD88^<-/->小鼠表现为低周转骨质疏松症,骨吸收和骨形成减少。这些结果表明,MyD88介导的信号对于IL-1和TLR配体诱导的破骨细胞发生和功能至关重要,MyD88在生理上参与骨转换。少
英文摘要
LPS is a potent stimulator of bone resorption in inflammatory diseases caused by bacteria. Bacterial lipoprotein/lipopeptides are also pathogen-specific molecular patterns. Toll-like receptor 4 (TLR4) is identified as the signaling receptor for LPS. The complex of TLR6 and TLR2 recognizes diacyl lipopeptide. The signaling cascade of TLR is similar to that of IL-1 receptors, because both TLR and IL-1receptors use MyD88 as a common signaling molecule. Toll-IL-1 receptor domain-containing adapter inducing interferon-γ (TRIF)-mediated signals are also shown to be involved in LPS-induced MyD88-independent pathway. Using MyD88-deficient (MyD88^<-/->) mice and TRIF-deficient (TRIF^<-/->) mice, we examined roles of MyD88 and TRIF in osteoclast differentiation and function. LPS, diacyl lipopeptide (DL) and IL-1 stimulated osteoclastogenesis in co-cultures of osteoblasts and hemopoietic cells obtained from TRIF^<-/-> mice but not MyD88^<-/-> mice. Bone marrow hemopoietic cells from MyD88^<-/-> m … More ice and TRIF^<-/-> mice similarly differentiated into osteoclasts in response to RANKL plus M-CSF. LPS, DL and IL-1 stimulated RANKL mRNA expression in TRIF^<-/-> osteoblasts but not MyD88^<-/-> osteoblasts, suggesting that only MyD88-mediated signal in osteoblasts was important for RANKL expression in response to those factors. This finding was particularly interesting, because both MyD88-dependent and TRIF-dependent pathways are essential for LPS-induced cytokine production in macrophages. Indeed, LPS failed to stimulate IL-6 production in TRIF^<-/-> bone marrow macrophages. But, LPS could stimulate IL-6 production in TRIF^<-/-> osteoblasts. LPS and IL-1 enhanced the survival of TRIF^<-/-> osteoclasts but not MyD88^<-/-> osteoclasts. DL did not support the survival of osteoclasts, because of the lack of TLR6 in osteoclasts. TRIF-related adaptor molecule (TRAM) was shown to be essentially involved in the TRIF-mediated signaling pathway. Interestingly, macrophages expressed both TRIF and TRAM mRNAs, while osteoblasts and osteoclasts expressed only TRIF mRNA. The fact that TRIF-mediated signals are not required for LPS-induced RANKL and IL-6 expression in osteoblasts and for osteoclast survival may be related to the lack of TRAM expression in osteoblasts and osteoclasts. Bone histomorphometry showed that MyD88^<-/-> mice exhibited low turnover osteoporosis with reduced bone resorption and formation. These results suggest that the MyD88-mediated signal is essential for the osteoclastogenesis and function induced by IL-1 and TLR ligands, and that MyD88 is physiologically involved in bone turnover. Less
期刊论文(50)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Itoh K.et al.: "LPS promotes the survival of osteoclasts via toll-like receptor 4, but cytokine production of osteoclasts in response to LPS is different from that of macrophages."Journal of Immunology. 170・7. 3688-3695 (2003)
Itoh K.等人:“LPS通过Toll样受体4促进破骨细胞的存活,但破骨细胞响应LPS的细胞因子产生与巨噬细胞不同。”免疫学杂志170・7。 2003)
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
MyD88 but not TRIP is essential for osteoclastogenesis induced by lipopolysaccharide, diacyl lipopeptide and IL-1α.
MyD88 而不是 TRIP 对于脂多糖、二酰基脂肽和 IL-1α 诱导的破骨细胞生成至关重要。
DOI:
--
发表时间:
2004
期刊:
J Exp Med 200
影响因子:
--
作者:
[Sato N, et al.]
通讯作者:
et al.
骨吸収と骨形成の共役機構
骨吸收与骨形成的耦合机制
DOI:
--
发表时间:
2004
期刊:
腎と骨代謝 17・2
影响因子:
--
作者:
[清水武彦, 韓娟, 岡本春憲, 新井陽子, 前田隆秀, Takahisa TOYAMA et al., Sato N et al., 中村美どり 他]
通讯作者:
中村美どり 他
Suda K.et al.: "Suppression of osteoprotegerin expression by prostaglandin E_2 is crucially involved in LPS-induced osteoclast formation."Journal of Immunology. 172・4. 2504-2510 (2004)
Suda K.等人:“前列腺素E_2对骨保护素表达的抑制对于LPS诱导的破骨细胞形成至关重要。”免疫学杂志172·4(2004)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
DOI:
10.1074/jbc.m500926200
发表时间:
2005-06-24
期刊:
JOURNAL OF BIOLOGICAL CHEMISTRY
影响因子:
4.8
作者:
[Kobayashi, Y, Take, I, Takahashi, N]
通讯作者:
Takahashi, N
共 21 条
Exploration of seeds for development of a new drug targeting Bone-Vascular-Spleen axis
-
批准号:25670793
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$2.41万
-
财政年份:2013
-
负责人:UDAGAWA Nobuyuki
-
依托单位:
Analysis of bone remodeling mechanism between osteoblasts and osteoclasts for the alveolar bone regeneration
-
批准号:24390417
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$11.73万
-
财政年份:2012
-
负责人:UDAGAWA Nobuyuki
-
依托单位:
Basic research on development of new treatment of alveolar bone regeneration
-
批准号:21390498
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$11.73万
-
财政年份:2009
-
负责人:UDAGAWA Nobuyuki
-
依托单位:
Elucidation of the regulated mechanism of bone metabolism by osteoclastic transcytosis.
-
批准号:19390476
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$12.15万
-
财政年份:2007
-
负责人:UDAGAWA Nobuyuki
-
依托单位:
Establishment of periodontitis treatment method by inhibition of RANK-Toll like receptor signal
-
批准号:17390497
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$9.98万
-
财政年份:2005
-
负责人:UDAGAWA Nobuyuki
-
依托单位:
Analysis of signal transduction of osteoclast differentiation factor (RANKL) in alveolar bone destruction
-
批准号:13470394
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$9.28万
-
财政年份:2001
-
负责人:UDAGAWA Nobuyuki
-
依托单位:
The physiological role of osteoclast differentiation factor.
-
批准号:11470393
-
项目类别:Grant-in-Aid for Scientific Research (B).
-
资助金额:$3.65万
-
财政年份:1999
-
负责人:UDAGAWA Nobuyuki
-
依托单位:
Mechanism of osteoclastogenesis inhibitory action by interleukin 18
-
批准号:09671905
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.3万
-
财政年份:1997
-
负责人:UDAGAWA Nobuyuki
-
依托单位:
国内基金
海外基金
登录
查看更多内容
异类叶升麻苷通过阻断TLR4二聚体化抑制MyD88/TRIF信号通路减轻重症急性胰腺炎急性肺损伤的作用机制研究
-
批准号:81904041
-
项目类别:青年科学基金项目
-
资助金额:21.0万元
-
批准年份:2019
-
负责人:王彬
-
依托单位:
异类叶升麻苷通过阻断TLR4二聚体化抑制MyD88/TRIF信号通路减轻重症急性胰腺炎急性肺损伤的作用机制研究
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:21万元
-
批准年份:2019
-
负责人:王彬
-
依托单位:
天然免疫STING/MAVS/TRIF/MyD88信号通路在HBsAg阳性母亲婴儿乙肝疫苗无/弱应答中的作用
-
批准号:81872677
-
项目类别:面上项目
-
资助金额:57.0万元
-
批准年份:2018
-
负责人:冯永亮
-
依托单位:
针刺干预创伤性脑损伤及其对TLR4/MyD88/TRIF介导的小胶质细胞活化的调控机制研究
-
批准号:81704156
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:朱明敏
-
依托单位:
MyD88/TRIF共激活模式在RSV感染后激素抗炎效应的作用及机制研究
-
批准号:81300007
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:谢晓虹
-
依托单位:
基于"补肾健脾方"调控树突细胞TLRs/MyD88/TRIF通路探讨"扶正"治则在慢乙肝治疗中的作用机制
-
批准号:81302891
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王磊
-
依托单位:
非酒精性脂肪肝小鼠TLR4 的MyD88和TRIF信号通路与胰岛素抵抗的相关研究
-
批准号:81260078
-
项目类别:地区科学基金项目
-
资助金额:46.0万元
-
批准年份:2012
-
负责人:梁志清
-
依托单位:
胡薄荷酮对TLR信号转导通路MyD88和TRIF途径的影响
-
批准号:81102867
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:解宇环
-
依托单位:
HSV-2对人宫颈上皮细胞TLR4依赖的Mal/MyD88和TRAM/TRIF通路的激活
-
批准号:81072419
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:李晖
-
依托单位:
MyD88/Trif基因联合沉默的不成熟树突状细胞在诱导小肠移植免疫耐受中的作用
-
批准号:30872532
-
项目类别:面上项目
-
资助金额:31.0万元
-
批准年份:2008
-
负责人:吴文溪
-
依托单位: